However, the alternative upregulation of TIM-3 by PD-1-bound CD8+ T cells in response to anti-PD-1 treatment in a mouse lung adenocarcinoma model and in lung cancer patients (75) implies this occurrence can compromise the effectiveness of checkpoint blockade. Here, PDCD1 is linked to lung carcinoma.